Abstract
Introduction

CD8
+ cytotoxic T lymphocytes (CTL) are essential for immune protection against intracellular pathogens and tumors. Various forms of vaccines have been designed specifically to elicit CTL responses. In particular, viral vectors are being widely studied for use in gene-based vaccine strategies due to their ability to deliver antigens into the antigen-processing pathways needed to stimulate MHC class I-restricted CTL responses 1, 2 . Furthermore, the frequency of transgenespecific T cells can be further increased by combining recombinant viral vectors in heterologous prime-boost regimens 3, 4 . A central role for dendritic cells (DCs) in priming CD8 + T cells has been well-established following viral infection or vaccination 5, 6 . This includes the transportation of viral antigens by migratory DCs to draining lymph nodes or spleen and subsequent antigen presentation by lymphoid residential DCs 7, 8 . Upon activation, effector and effector memory T cells enter the circulation and peripheral tissues, whereas central memory T cells home to the secondary lymphoid organs [9] [10] [11] . This differential distribution suggests that similar to the priming process, booster amplification of central memory T cells also requires cooperation between migratory and residential DCs. However, acceleration of CD8 + T cell boosting may be limited by circulating CTL that can readily kill migratory DCs in peripheral tissues and prevent their interaction with central memory T cells 12 . Indeed, we, and others have provided evidence that re-administered DC vaccines fail to reach lymphoid organs in the presence of vigorous CTL response [13] [14] [15] .
As another major subset of APCs, B cells share many biological features with DCs, such as a high level of MHC expression and the capacity to produce cytokines that enable them to regulate
antigen-specific T cell responses. Thus, there is an increasing interest in using B cells as an
For personal use only. on December 27, 2017. by guest www.bloodjournal.org From 4 alternative to DCs as cell-based vaccines for immunotherapy 16, 17 . In particular, large numbers of autologous B cells can be readily prepared from the blood of patients and further expanded ex vivo, providing an additional advantage over DCs, which are not readily expanded when differentiated from monocytes, to meet therapeutic schedules where multiple vaccinations are required 18, 19 . Furthermore, intravenously administered B cells readily migrate to secondary lymphoid organs, offering a potentially more effective platform to deliver antigens to the primary site of T cell activation. However, whether B cell-based vaccines can escape CTL-mediated elimination during booster immunization has not been studied.
In the present study, we compared the capacity of ex vivo generated DCs and B cells to elicit For personal use only. on December 27, 2017. by guest www.bloodjournal.org From 6 KAVYNFATM) was purchased from the Dalton Chemical Laboratory (Toronto, Canada).
Peptides were dissolved in distilled water and stored at -20°C.
Cell culture and viral infection
B cells were purified from the spleen of wild type C57BL/6 mice using negative selection kits (Miltenyi Biotec, Germany). Purified B cells were cultured with adipocyte-conditioned medium supplemented with 20 ng/ml IL-2, Imiquimod (IQ), and Phorbol 12, 13-dibutyrate (PDB) at the concentration of 2 x 10 6 B cells/ml, as previously described 23 . Three days after culture, B cells were pulsed with VSV or Vac vectors at an MOI of 25 for 2-24 h. Viral vector-pulsed freshly isolated B cells were used as a comparison.
The procedure for generating bone marrow-derived DCs has been described previously 24 . Seven days after culture, DC infection was carried out as described above.
Viral titration of culture supernatant
Supernatants from B cell or DC culture were collected at the start of and 2 h after infection following centrifugation to remove cells. Vero cells were infected with a dilution series of these collected supernatants or purified VSV-GP33 (as positive control) in triplicate for 1 h prior to overlay of 1% agarose gel onto the culture dish. Viral titers were quantified by the plaque assay after further incubation for 24-48 h. antibodies and analyzed by flow cytometry to determine the number of migrating B cells or DCs.
Confocal microscopy
In addition to flow cytometric analysis as described above, spleen and lymph node samples were also collected and made into 8 μ m frozen sections for confocal microscopic imaging. After fixation with 1% paraformaldehyde and subsequent Fc blocking, slides were stained with PETexas Red-conjugated rat anti murine B220 (1:800). The prepared slides were evaluated using a confocal laser scanning microscope (LSM 510 Meta imaging system, Carl Zeiss). Excitation of fluorescent dye was at 590 nm for PE-Texas Red labeled B220.
Chimeras
To determine the role of B cells in antigen presentation following B/VSV boosting, lethally irradiated (2 x 550 Rads; 48 h interval) wild type C57BL/6 mice received 5 x 10 6 bone marrow from B -/-mice plus 1 x 10 6 bone marrow from WT (
The only difference between these two chimeras is that B cells in the latter (B -/-+ K b D b-/-) are deficient for MHC class I and therefore incapable of presenting antigen to CD8 + T cells.
To determine whether endogenous DCs were required in B/VSV-induced secondary T cell expansion, CD11c-DTR chimeric mice were similarly prepared by transferring CD11c-DTR transgenic mouse-derived bone marrow into lethally irradiated C57BL/6 recipients (CD11c→WT), which allows multiple injections of diphtheria toxin (DT) to deplete and maintain the absence of CD11c + DCs. As controls for both chimeras, lethally irradiated WT mice were reconstituted with wild type bone marrow (WT→WT). Mice were given three months to reconstitute their hematopoietic system (confirmed by flow cytometry) prior to experimentation.
Adoptive T cell transfer
To avoid misinterpretation of results from CD11c chimeric mice where diphtheria toxin may also remove some activated CD8 + T cells that express CD11c, a group of wild type congenic mice could boost a significant CTL response, whereas the same number of VSV-GP33-infected DCs (DC/VSV-GP33) failed to provoke secondary T cell expansion, suggesting that B cells are superior to DCs for eliciting a rapid recall T cell response. We excluded the possibility that i.v.
injection might represent a suboptimal route for DC vaccination because footpad injection with the DCs also failed to generate a boosting effect (Fig. 1a) . Since cultured B cells appeared to be more potent than their fresh counterparts and could be readily expanded, we chose to use cultured B cells for all subsequent studies.
We next increased the interval between priming and boosting to allow for the primary immune response to wane. As expected, DC/VSV-GP33 were able to boost antigen-specific CD8 + T cell responses on day 30 post Vac-GP33 priming, consistent with the notion that pre-existing effector
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T cells prevent excessive antigen presentation by DCs (Fig. 1b ) 12, 15 . Interestingly, B/VSV-GP33 still achieved a better boosting response compared to DC/VSV-GP33, suggesting that virusloaded B cells are superior for generating secondary antigen specific T cell responses with or without the presence of pre-existing CTLs.
The ability of B cells to boost secondary T cell responses is not limited by viral vectors or target antigens
To determine whether the ability of B/VSV to boost T cell responses was antigen dependent, we For personal use only. on December 27, 2017. by guest www.bloodjournal.org From
Virus-pulsed B cells do not present the target antigen
To determine whether viral infection may alter the susceptibility of B cells to CTL killing, we quantitated transgene expression in B cells and DCs following infection with VSV-GFP. To our surprise, while >70% DCs were GFP positive, very few B cells were directly infected by the virus (Fig. 3a) . This observation prompted us to hypothesize that VSV-pulsed B cells may function as a carrier to deliver viral vectors instead of mediating direct antigen presentation. To To firmly establish the necessity of B cells as a carrier to deliver boosting virus, we sought to
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determine whether direct injection of the same amount of VSV could elicit secondary T cell responses. At an MOI of 25, we determined that 3 x 10 6 B cells carried 2 x 10 6 pfu VSV in total after 2 h infection (as described in Materials and Methods). Direct injection with 2 x 10 6 or as high as 1 x 10 8 pfu (not shown) VSV-GP33 failed to boost memory T cell responses (Fig. 3c) ,
suggesting that B cells are critically required to deliver and/or amplify VSV-mediated antigen presentation by host APCs.
To determine whether B/VSV can also boost CD8 + T cell responses in mice that have a preexposure to VSV, we immunized mice with VSV-GP33 and then, 14 days later, boosted them with either VSV-GP33 or B cells pulsed with VSV-GP33. As expected, a minimal expansion of GP33-specific CD8 + T cells was observed by VSV-GP33 boosting, likely due to neutralizing antibodies against VSV that attenuate the boosting efficacy (see Supplementary Fig. 2) .
Surprisingly, however, B/VSV-GP33 boosted a strong CTL response suggesting that a B cellbased vaccination platform may be able to bypass both pre-existing CTL and neutralizing antibodies allowing for rapid, homologous prime-boosting.
Injected B cells can be recovered in the secondary lymphoid organs and are primarily localized to the follicular regions
Having established a role for virus-exposed B cells as carriers, we next sought to determine whether B cells migrate to secondary lymphoid organs where central memory T cells reside.
Mice were pre-immunized with Ad-GP33 for 14 days to establish GP33 specific immunity prior to i.v. delivery of CFSE-labeled, VSV-GP33-exposed B cells. Figure 4a and b show that a significant number of injected B cells could be recovered from both spleen and lymph nodes in
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To further visualize the localization of injected B cells within secondary lymphoid organs, spleen and lymph node sections were examined using confocal microscopy. The majority of injected B cells were located in the follicular regions (Fig. 4c) , suggesting that B cells may deliver viral vectors to this particular area where follicular APCs present antigens to memory T cells. This finding is consistent with the demonstration that the majority of cultured B cells possess a follicular B cell surface phenotype (see Supplementary Fig. 3 ) that may determine their homing capacity. Since effector T cells do not circulate through the marginal zone, antigen presentation by follicular APCs will not be affected by pre-existing CTL [26] [27] [28] [29] .
Early proliferation of antigen-specific CD8 + T cells occurs in spleen and lymph nodes, which requires host CD11c + APCs for antigen presentation
To determine that T cell expansion indeed occurs in secondary lymphoid organs, we treated mice with FTY720 to inhibit lymphocyte egress from lymphoid organs during boosting. T cell proliferation in the spleen and lymph notes was monitored by BrdU incorporation. Figure 5 shows that compared to the B/VSV-MT control, the earliest proliferation of GP33 specific CD8 + T cells was evident in both spleen and lymph nodes 48 hours post B/VSV-GP33 boosting.
Considering the possibility that endogenous B cells and DCs are both capable of presenting the booster antigen to expand memory T cells in the follicular areas, we generated two chimeric strains of mice to address their role in antigen presentation (schematic of chimeric mice
For personal use only. on December 27, 2017. by guest www.bloodjournal.org From preparation shown in Supplementary Fig. 4) (Fig. 6a) . The secondary expansion was not attenuated when the B cells were unable to present antigen on MHC class I (Fig. 6a) demonstrating that antigen presentation by endogenous B cells was not required. The second chimeras were made using bone marrow cells from CD11c-DTR transgenic mice to reconstitute lethally irradiated wild-type mice (CD11c→WT). As such, multiple doses of diphtheria toxin (DT) could be delivered to deplete and maintain the absence of CD11c + DCs (protocols for DT injection shown in Supplementary Fig. 4 ). Figure 6B shows that DT injection abrogated the boosting effect of B/VSV-GP33 in CD11c-DTR chimeric mice but not wild type control ( We, and others have previously shown that repeated immunizations using DC-based vaccines failed to increase the number of antigen-specific CD8 + T cells 13, 32 . Evidently CD8 + CTL activated by primary immunization were efficient to eliminate antigen-carrying DCs in peripheral tissues, preventing access of central memory T cells to booster antigens 14, 33, 34 .
Moreover, a recent study has shown that effector T cells can re-enter reactive lymph nodes and attenuate antigen presentation by killing newly arrived DCs and antigen-loaded residential DCs 35 . These data clearly demonstrate that the efficacy of booster immunizations which rely on DCs for antigen transportation will be limited by this CTL-mediated negative feedback mechanism, especially during primary and chronic immune responses. The data presented in the current study are consistent with this notion where boosting with vector-infected DCs or direct Although several studies have argued that DCs can be modified to increase their resistance to CTL killing, their migration capacity remains a challenge for the development of DC-based vaccines [39] [40] [41] . We, and others have shown that only a small fraction (<1%) of locally inoculated DCs can migrate to the draining lymph nodes, whereas most remain at the site of immunization 13, 42, 43 . Intravenously delivered DCs are also insufficient to traffic to the spleen and lymph nodes. In contrast, we demonstrate in the current study that intravenously administered B cells could be efficiently recovered from spleen and all lymph nodes suggesting that vectorpulsed B cells can deliver antigen and mediate T cell expansion in multiple lymphoid organs.
VSV has proven to be a potent vaccine vector for immunotherapy for both cancer and infectious diseases 38, [44] [45] [46] . However, rapid induction of neutralizing antibodies against VSV prevents 
